Trebananib: Additional Phase III data

Additional data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE